Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies.

[1]  F. Eckstein,et al.  Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes. , 1991, Science.

[2]  M. Whitt,et al.  A new cationic liposome reagent mediating nearly quantitative transfection of animal cells. , 1991, BioTechniques.

[3]  L. Huang,et al.  A novel cationic liposome reagent for efficient transfection of mammalian cells. , 1991, Biochemical and biophysical research communications.

[4]  G. Nabel,et al.  Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. , 1993, Human gene therapy.

[5]  P. D. Cook,et al.  Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. , 1993, Journal of medicinal chemistry.

[6]  P. Low,et al.  Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. , 1994, The Journal of biological chemistry.

[7]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[8]  M. Carmell,et al.  Posttranscriptional Gene Silencing in Plants , 2006 .

[9]  P. Sharp,et al.  RNAi Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals , 2000, Cell.

[10]  A. Fire,et al.  Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. , 2000, Molecular cell.

[11]  G. Nickenig,et al.  Angiotensin AT1 receptor over-expression in hypercholesterolaemia , 2000, Annals of medicine.

[12]  K. Kataoka,et al.  Block copolymer micelles for drug delivery: design, characterization and biological significance. , 2001, Advanced drug delivery reviews.

[13]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[14]  K. Egashira,et al.  [Angiotensin II receptor and oxidative stress]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.

[15]  T. Allen.  Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.

[16]  Stacy L DeRuiter,et al.  RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Stevenson,et al.  Modulation of HIV-1 replication by RNA interference , 2002, Nature.

[18]  Ali Ehsani,et al.  Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells , 2002, Nature Biotechnology.

[19]  Henning Urlaub,et al.  Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi , 2002, Cell.

[20]  B. Clotet,et al.  Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication , 2002, AIDS.

[21]  J. Church,et al.  siRNA-DIRECTED INHIBITION OF HIV-1 INFECTION , 2003, Pediatrics.

[22]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[23]  J. M. Thomson,et al.  Argonaute2 Is the Catalytic Engine of Mammalian RNAi , 2004, Science.

[24]  B. Dalby,et al.  Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. , 2004, Methods.

[25]  Ralf Bartenschlager,et al.  Alternative Approaches for Efficient Inhibition of Hepatitis C Virus RNA Replication by Small Interfering RNAs , 2004, Journal of Virology.

[26]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[27]  G. Hannon,et al.  Crystal Structure of Argonaute and Its Implications for RISC Slicer Activity , 2004, Science.

[28]  M. Manoharan.  RNA interference and chemically modified small interfering RNAs. , 2004, Current opinion in chemical biology.

[29]  Matthias John,et al.  Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. , 2004, Bioorganic & medicinal chemistry letters.

[30]  A. Chakraborty,et al.  GnT-V, macrophage and cancer metastasis: A common link , 2004, Clinical & Experimental Metastasis.

[31]  K. Alexander,et al.  RNA interference using boranophosphate siRNAs: structure-activity relationships. , 2004, Nucleic acids research.

[32]  Anton J. Enright,et al.  Human MicroRNA Targets , 2004, PLoS biology.

[33]  Jianjun Hu,et al.  Synthesis of carbamate-linked lipids for gene delivery. , 2005, Bioorganic & medicinal chemistry letters.

[34]  R. Schiffelers,et al.  Transporting silence: design of carriers for siRNA to angiogenic endothelium. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[35]  Anil K Sood,et al.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. , 2005, Cancer research.

[36]  Wei Ge,et al.  Synthetic shRNAs as potent RNAi triggers , 2005, Nature Biotechnology.

[37]  T. Rana,et al.  Specific and potent RNAi in the nucleus of human cells , 2005, Nature Structural &Molecular Biology.

[38]  T. Ochiya,et al.  Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  H. Paulson,et al.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Mandel,et al.  Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  Judy Lieberman,et al.  Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors , 2005, Nature Biotechnology.

[42]  S. Akira,et al.  Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7 , 2005, Nature Medicine.

[43]  Xuechi Lin,et al.  RNA interference remarkably suppresses bcl-2 gene expression in cancer cells in vitro and in vivo , 2005, Cancer biology & therapy.

[44]  Mark E. Davis,et al.  Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. , 2005, Cancer research.

[45]  Dongliang Liu,et al.  Synthesis and characterization of a series of carbamate-linked cationic lipids for gene delivery , 2005, Lipids.

[46]  L. Lim,et al.  Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. , 2006, RNA.

[47]  J. Glorioso,et al.  Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. , 2006, Gene therapy.

[48]  M. Woodle,et al.  Harnessing in vivo siRNA delivery for drug discovery and therapeutic development , 2006, Drug Discovery Today.

[49]  Anastasia Khvorova,et al.  3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets , 2006, Nature Methods.

[50]  L. Lim,et al.  Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. , 2006, RNA.

[51]  P. Campochiaro.  Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders , 2006, Gene Therapy.

[52]  M. K. Sapru,et al.  Silencing of human α-synuclein in vitro and in rat brain using lentiviral-mediated RNAi , 2006, Experimental Neurology.

[53]  M. C. Bohn,et al.  Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. , 2006, Experimental neurology.

[54]  J. Glorioso,et al.  Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-β peptide in vivo , 2006, Gene Therapy.

[55]  M. Zhang,et al.  Redox signalling involving NADPH oxidase-derived reactive oxygen species. , 2006, Biochemical Society transactions.

[56]  R. Davisson,et al.  NADPH oxidases of the brain: distribution, regulation, and function. , 2006, Antioxidants & redox signaling.

[57]  J. Rossi,et al.  RNAi therapeutics: principles, prospects and challenges. , 2007, Advanced drug delivery reviews.

[58]  A. Judge,et al.  2'-O-methyl-modified RNAs act as TLR7 antagonists. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[59]  Anna Moore,et al.  In vivo imaging of siRNA delivery and silencing in tumors , 2007, Nature Medicine.

[60]  shRNAs Targeting Hepatitis C: Effects of Sequence and Structural Features, and Comparison with siRNA , 2007 .

[61]  D. Leake,et al.  shRNAs targeting hepatitis C: effects of sequence and structural features, and comparision with siRNA. , 2007, Oligonucleotides.

[62]  M. Savva,et al.  Effect of spacer attachment sites and pH-sensitive headgroup expansion on cationic lipid-mediated gene delivery of three novel myristoyl derivatives. , 2007, Biophysical chemistry.

[63]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[64]  B. Davidson,et al.  Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. , 2008, RNA.

[65]  K. Ui-Tei,et al.  Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect , 2008, Nucleic acids research.

[66]  D. Leake,et al.  Stability study of unmodified siRNA and relevance to clinical use. , 2008, Oligonucleotides.

[67]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[68]  Robert Langer,et al.  Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates , 2008, Proceedings of the National Academy of Sciences.

[69]  Martin J. Simard,et al.  Argonaute proteins: key players in RNA silencing , 2008, Nature Reviews Molecular Cell Biology.

[70]  A. Chakraborty,et al.  The cancer cell--leukocyte fusion theory of metastasis. , 2008, Advances in cancer research.

[71]  Xian Jun Loh,et al.  Cyclodextrin-based supramolecular architectures: syntheses, structures, and applications for drug and gene delivery. , 2008, Advanced drug delivery reviews.

[72]  L. J. Lee,et al.  Targeted Delivery Systems for Oligonucleotide Therapeutics , 2009, The AAPS Journal.

[73]  C. Noe,et al.  A proteomic study reveals unspecific apoptosis induction and reduction of glycolytic enzymes by the phosphorothioate antisense oligonucleotide oblimersen in human melanoma cells. , 2009, Journal of proteomics.

[74]  G. Bonvento,et al.  Sustained effects of nonallele‐specific Huntingtin silencing , 2009, Annals of neurology.

[75]  R. Donnelly,et al.  Microneedle-based drug delivery systems: Microfabrication, drug delivery, and safety , 2010, Drug delivery.

[76]  Peixuan Guo,et al.  Engineering RNA for Targeted siRNA Delivery and Medical Application , 2010, Advanced Drug Delivery Reviews.

[77]  Paul C. Wang,et al.  Circumventing tumor resistance to chemotherapy by nanotechnology. , 2010, Methods in molecular biology.

[78]  Jun Li,et al.  Multifunctional Nanoparticles Delivering Small Interfering RNA and Doxorubicin Overcome Drug Resistance in Cancer* , 2010, The Journal of Biological Chemistry.

[79]  E. Masliah,et al.  Lentivirus-expressed siRNA vectors against Alzheimer disease. , 2010, Methods in molecular biology.

[80]  D. Leake,et al.  Silencing of reporter gene expression in skin using siRNAs and expression of plasmid DNA delivered by a soluble protrusion array device (PAD). , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[81]  K. High,et al.  Viral vector-mediated RNA interference. , 2010, Current opinion in pharmacology.

[82]  R. Hickerson,et al.  First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[83]  M. Czech,et al.  RNAi-based therapeutic strategies for metabolic disease , 2011, Nature Reviews Endocrinology.

[84]  Daniel G. Anderson,et al.  Synergistic silencing: combinations of lipid-like materials for efficacious siRNA delivery. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[85]  G. Zhaori,et al.  Potential clinical applications of siRNA technique: benefits and limitations , 2011, European journal of clinical investigation.

[86]  J. Goodchild.  Therapeutic Oligonucleotides , 2011, Methods in Molecular Biology.

[87]  D. Rao,et al.  RNA Interference and Cancer Therapy , 2011, Pharmaceutical Research.

[88]  Hong Shen,et al.  In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA. , 2011, Basic & clinical pharmacology & toxicology.

[89]  A. R. Kulkarni,et al.  Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review , 2011, Expert opinion on drug delivery.

[90]  S. Mallapragada,et al.  The mechanism of selective transfection mediated by pentablock copolymers; part II: nuclear entry and endosomal escape. , 2011, Acta biomaterialia.

[91]  Jun Wang,et al.  Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[92]  D. Peer,et al.  RNAi-based nanomedicines for targeted personalized therapy. , 2012, Advanced drug delivery reviews.

[93]  Liling Wu,et al.  Small interfering RNA targeted to secretory clusterin blocks tumor growth, motility, and invasion in breast cancer. , 2012, Acta biochimica et biophysica Sinica.

[94]  Jung-Hwan Park,et al.  Microneedles for drug and vaccine delivery. , 2012, Advanced drug delivery reviews.

[95]  Y. Maehara,et al.  Expression of MicroRNA miR-122 Facilitates an Efficient Replication in Nonhepatic Cells upon Infection with Hepatitis C Virus , 2012, Journal of Virology.

[96]  S. Alavian,et al.  Therapeutic potential of RNA interference: a new molecular approach to antiviral treatment for hepatitis C , 2012, Journal of viral hepatitis.

[97]  Golovanova Ev.  [Treatment of chronic viral hepatitis: achievements and prospects]. , 2012 .

[98]  Shubiao Zhang,et al.  Non-viral vectors for the mediation of RNAi. , 2012, Bioorganic chemistry.

[99]  C. Dass,et al.  Role of Bcl‐2 in tumour cell survival and implications for pharmacotherapy , 2012, The Journal of pharmacy and pharmacology.

[100]  E. V. Golovanova.  [Treatment of chronic viral hepatitis: achievements and prospects]. , 2012, Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology.

[101]  M. Ishida,et al.  miRNA-Based Therapeutic Strategies , 2013, Current Pathobiology Reports.

[102]  K. Saini,et al.  RNA interference therapeutics for cancer: challenges and opportunities (review). , 2012, Molecular medicine reports.

[103]  B. Strooper,et al.  Non-coding RNAs with essential roles in neurodegenerative disorders , 2012, The Lancet Neurology.

[104]  E. Cevher,et al.  Gene Delivery Systems: Recent Progress in Viral and Non-Viral Therapy , 2012 .

[105]  S. Ignacimuthu,et al.  RNA interference as a plausible anticancer therapeutic tool. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[106]  W. Mark Saltzman,et al.  Therapeutic siRNA: Principles, Challenges, and Strategies , 2012, The Yale journal of biology and medicine.

[107]  A. Johnson,et al.  PVN adenovirus-siRNA injections silencing either NOX2 or NOX4 attenuate aldosterone/NaCl-induced hypertension in mice. , 2012, American journal of physiology. Heart and circulatory physiology.

[108]  Enzo Di Fabrizio,et al.  Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy , 2012, International journal of nanomedicine.

[109]  D. Leake,et al.  Inhibition of CD44 gene expression in human skin models, using self-delivery short interfering RNA administered by dissolvable microneedle arrays. , 2012, Human Gene Therapy.

[110]  An RNA Alternative to Human Transferrin: A New Tool for Targeting Human Cells , 2012, Molecular therapy. Nucleic acids.

[111]  Leaf Huang,et al.  Lipid-based vectors for siRNA delivery , 2012, Journal of drug targeting.

[112]  P. Lu,et al.  Effect of GPE-AGT nanoparticle shRNA transfection system mediated RNAi on early atherosclerotic lesion. , 2012, International journal of clinical and experimental pathology.

[113]  Guang-Yuh Chiou,et al.  Non-viral delivery of RNA interference targeting cancer cells in cancer gene therapy. , 2012, Current gene therapy.

[114]  N. K. Jain,et al.  A review of nanocarriers for the delivery of small interfering RNA. , 2012, Biomaterials.

[115]  D. Azar,et al.  Corneal neovascularization: an anti-VEGF therapy review. , 2012, Survey of ophthalmology.

[116]  S. Barth,et al.  An aptamer-siRNA chimera silences the eukaryotic elongation factor 2 gene and induces apoptosis in cancers expressing αvβ3 integrin. , 2013, Nucleic acid therapeutics.

[117]  B. Hyman,et al.  Mechanisms of protein seeding in neurodegenerative diseases. , 2013, JAMA neurology.

[118]  Christopher H Contag,et al.  Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[119]  Fei Li,et al.  Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles. , 2013, Current pharmaceutical design.

[120]  K. Choy,et al.  MicroRNA-182 plays an onco-miRNA role in cervical cancer. , 2013, Gynecologic oncology.

[121]  Yupei Zhao,et al.  RNA interference-mediated silencing of VEGF and bFGF suppresses endostatin secretion in pancreatic carcinoma cells , 2013, Oncology letters.

[122]  J. Jun,et al.  Chitosan nanoparticle carrying small interfering RNA to platelet-derived growth factor B mRNA inhibits proliferation of smooth muscle cells in rabbit injured arteries , 2013, Vascular.

[123]  G. Desir,et al.  Does Kidney Disease Cause Hypertension? , 2013, Current Hypertension Reports.

[124]  D. Margolis,et al.  Prospects for Treatment of Latent HIV , 2013, Clinical pharmacology and therapeutics.

[125]  B. Bernstein,et al.  Epigenetic Reprogramming in Cancer , 2013, Science.

[126]  Howard L McLeod,et al.  Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed , 2013, Science.

[127]  Wei Zhang,et al.  Induction of apoptosis by chitosan/HPV16 E7 siRNA complexes in cervical cancer cells. , 2013, Molecular medicine reports.

[128]  D. Maysinger,et al.  Hsp70 silencing with siRNA in nanocarriers enhances cancer cell death induced by the inhibitor of Hsp90. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[129]  Burton B. Yang,et al.  Friend or foe: the role of microRNA in chemotherapy resistance , 2013, Acta Pharmacologica Sinica.

[130]  Zhirong Wang,et al.  Downregulation of the GnT-V gene inhibits metastasis and invasion of BGC823 gastric cancer cells. , 2013, Oncology reports.

[131]  K. Vårum,et al.  Nanoparticle Mediated P-Glycoprotein Silencing for Improved Drug Delivery across the Blood-Brain Barrier: A siRNA-Chitosan Approach , 2013, PloS one.

[132]  Michael E. Davis,et al.  Functionalized dendrimer-based delivery of angiotensin type 1 receptor siRNA for preserving cardiac function following infarction. , 2013, Biomaterials.

[133]  D. Margolis,et al.  Erratum: Prospects for Treatment of Latent HIV (Clinical Pharmacology and Therapeutics (2013) 93 (46-56) DOI: 10.1038/clpt.2012.202) , 2013 .

[134]  M. Fakih.  The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer , 2013, Expert review of anticancer therapy.

[135]  R. Hoffman,et al.  VEGF-C ShRNA inhibits pancreatic cancer growth and lymphangiogenesis in an orthotopic fluorescent nude mouse model. , 2013, Anticancer research.